Prediction of CAR‐T Therapy In Vitro: Development of Biomimetic Models for CAR‐T Killing Effect Assessment
Small · 2025-09 · 21 (37)
DOI: 10.1002/smll.202503384 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Small, online erschienen am 13.08.2025. Verfasst von Xuan Sun und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Digital Medical Engineering, School of Biological Science and Medical Engineering, Southeast University, Nanjing, Jiangsu, 21…. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Biomimetics, Immunotherapy, Adoptive. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 177 Literaturangaben. Gefördert von: National Key R&D Program of China, Science and Technology Project of Jiangsu Province, Key R&D Program of Guangxi Province.
Abstract (Originalsprache)
Chimeric antigen receptor T (CAR‐T) cell therapy faces significant challenges in treating solid tumors, particularly due to tumor heterogeneity and the complex tumor microenvironment. These challenges highlight the need for reliable preclinical assessment models. Traditional in vivo models, commonly used for evaluating CAR‐T efficacy, often fail to adequately represent the human immune system context. In recent years, various in vitro models have been developed to better simulate the in vivo tumor environment and assess CAR‐T cell efficacy. This review summarizes the methodologies commonly employed in the construction of in vitro models, including traditional 2D cell cultures, spheroids, organoids, 3D bioprinting, and tumor‐on‐a‐chip models. Special emphasis is placed on creation of biomimetic tumor microenvironment in the organ‐on‐a‐chip models to evaluate the potency and safety of CAR‐T therapy in the context of solid tumors CAR‐T treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Digital Medical Engineering, School of Biological Science and Medical Engineering, Southeast University, Nanjing, Jiangsu, 210096, China.
- Jiangsu Avatarget Biotechnology Co., Ltd, Suzhou, 215163, China.
- HRYZ Biotech Co., Guangzhou, 510000, China.
ORCID-Profile: Zhongze Gu, Zaozao Chen
Förderung
- National Key R&D Program of China
- Science and Technology Project of Jiangsu Province
- Key R&D Program of Guangxi Province
- National Key Research and Development Program of China
Zitieren
APA
Sun, X., Zhang, Z., Zhao, W., Xu, S., Zhang, J., Zhuansun, X., Ye, J., Han, Y., Gu, Z., & Chen, Z. (2025). Prediction of CAR‐T Therapy In Vitro: Development of Biomimetic Models for CAR‐T Killing Effect Assessment. Small, 21(37). https://doi.org/10.1002/smll.202503384
Vancouver
Sun X, Zhang Z, Zhao W, Xu S, Zhang J, Zhuansun X, et al. Prediction of CAR‐T Therapy In Vitro: Development of Biomimetic Models for CAR‐T Killing Effect Assessment. Small. 2025;21(37). doi:10.1002/smll.202503384
BibTeX
@article{Sun2025,
author = {Sun, Xuan and Zhang, Zilin and Zhao, Wentao and Xu, Shihui and Zhang, Jing and Zhuansun, Xuemei and Ye, Jiexian and Han, Yanyan and Gu, Zhongze and Chen, Zaozao},
title = {Prediction of CAR‐T Therapy In Vitro: Development of Biomimetic Models for CAR‐T Killing Effect Assessment},
journal = {Small},
year = {2025},
volume = {21},
number = {37},
doi = {10.1002/smll.202503384}
}
EUVIMED